ISCA2 mutations manifest differentially from DARS2 mutations by Finsterer, Josef & Zarrouk-Mahjoub, Sinda
HAL Id: pasteur-02009056
https://hal-riip.archives-ouvertes.fr/pasteur-02009056
Submitted on 6 Feb 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
ISCA2 mutations manifest differentially from DARS2
mutations
Josef Finsterer, Sinda Zarrouk-Mahjoub
To cite this version:
Josef Finsterer, Sinda Zarrouk-Mahjoub. ISCA2 mutations manifest differentially from DARS2 mu-
tations. Metabolic Brain Disease, Springer Verlag, 2018, 33 (5), pp.1389-1390. ￿10.1007/s11011-018-
0253-z￿. ￿pasteur-02009056￿
COMMENTARY
ISCA2 mutations manifest differentially from DARS2 mutations
Josef Finsterer1 & Sinda Zarrouk-Mahjoub2
Received: 3 May 2018 /Accepted: 17 May 2018 /Published online: 22 May 2018
# Springer Science+Business Media, LLC, part of Springer Nature 2018
Letter to the Editor,
With interest we read the article by Toldo et al. about a 2-
months-old girl with severe, progressive mitochondrial disor-
der (MID) due to a compound heterozygous ISCA2 mutation,
phenotypically manifesting as leucencephalopathy, muscle
hypotonia, muscle weakness, paraspasticity, feeding difficul-
ties, and nystagmus (Toldo et al. 2018). The patient died at age
3 months from respiratory failure. The article raises a number
of comments and concerns.
Patients carrying ISCA2 mutations have not only been re-
ported by Toldo et al. and Al-Hassnan et al. 2015 (Al-Hassnan
et al. 2015) as pretended but also by Alfadhel et al. 2018
(Alfadhel et al. 2018). Alfadhel et al. described 10 patients
carrying ISCA2 mutations other than the founder muta-
tion c.229G > A (p.Gly77Ser) described by Al-Hassnan
et al. (Alfadhel et al. 2018) or the mutation c.334A > G/
(p.Ser112Gly) described by Toldo et al. (Toldo et al.
2018). In addition to neurodevelopmental regression,
leucencephalopathy, lactic acidosis, and nystagmus,
Alfadehl’s patients presented with epilepsy (n = 3), elevated
serum glycine (n = 3), elevated cerebral glycine (n = 2), and
optic atrophy (n = 10) (Alfadhel et al. 2018). Did Toldo’s case
ever develop seizures, were there indications for optic atrophy
on MRI or ophthalmologic investigations, or was serum/CSF
glycine elevated?
Before establishing the molecular diagnoses, the patient
was regarded to suffer from leucencephalopathy with
brainstem and spinal cord involvement and lactate elevation
(LBSL) and methylprednisolone was started. Which was the
rationale for applying steroids? In none of the patients report-
ed by Al-Hassnan or by Alfadhel were steroids applied.
Furthermore, there are no reports about patients with LBSL
who received steroids and who profited from their application.
Use of steroids in MIDs may have a broad range of different
effects (Finsterer and Frank 2015). Some patients may benefit
from steroids whereas others may have a fatal outcome
(Finsterer and Frank 2015). Is it conceivable that appli-
cation of steroids contributed to the progressive course
and the fatal outcome of the described patient? For how
long were steroids administered?
The spinal cord may not only be involved in patients with
LBSL or patients carrying a ISAC2 mutation (Finsterer and
Zarrouk-Mahjoub 2018). Among the specific MIDs spinal
cord involvement has been additionally described in Leigh-
syndrome, MERRF, KSS, IOSCA, MIRAS, PCH6, MELAS,
CPEO, and LHON (Finsterer and Zarrouk-Mahjoub 2018).
Additionally, non-specific MIDs due to mutations in SURF1,
tRNA(Glu), or POLG1,may present with spinal cord involve-
ment (Finsterer and Zarrouk-Mahjoub 2018).
MIDs are usually multisystem disorders either at onset or
develop affection ofmultiple organs during the disease course.
Particularly in the early stages multiorgan involvement may
be subclinical or only mildly manifesting why these patients
need to be prospectively investigated for involvement of the
eyes, ears, endocrine organs, heart, intestines, kidneys, bone
marrow, bones, or the skin. Was the presented patient prospec-
tively investigated for multisystem MID (MIMODS)?
Since biochemical investigations of the muscle biopsy
revealed complex-II and complex-IV deficiency in
Toldo’s case, it is conceivable that their patient addi-
tionally had at least myopathy.
The authors state that there was restricted diffusion of white
and greymatter (Toldo et al. 2018). Restricted diffusionmeans
DWI hyperintesity and ADC hypointensity. However, no
DWI sequences are presented.
In summary, this interesting report could be strengthened
by discussing Alfadhel’s cases and the variable phenotype, by
investigating for multisystem affection, by discussing the
Josef Finsterer and Sinda Zarrouk-Mahjoub contributed equally to this
work.
* Josef Finsterer
fifigs1@yahoo.de
1 Krankenanstalt Rudolfstiftung, Postfach, 20 1180 Vienna, Austria
2 Pasteur Institute of Tunis, University of Tunis El Manar and
Genomics Platform, Tunis, Tunisia
Metabolic Brain Disease (2018) 33:1389–1390
https://doi.org/10.1007/s11011-018-0253-z
application of steroids, and by specifying the type of spinal
cord abnormalities detected.
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